Delve Health and AliveCor Forge Partnership to Innovate Cardiology Digital Healthcare Solutions

Wednesday, February 07, 2024

Delve Health, a leading innovator in digital healthcare and decentralized clinical trial biotechnology, has announced an exciting collaboration with AliveCor. Together, they plan to integrate AliveCor's KardiaMobile® 6L, recognized as the world's most clinically-validated personal electrocardiogram (EKG) device, into the LiveCare Link + smart RPM gateway. This partnership aims to spur new research initiatives, streamline drug development processes, and explore innovative treatments to address unmet medical needs. By enhancing healthcare efficiency and precision, the collaboration strives to make a significant impact on patient lives and contribute to overall well-being.

The KardiaMobile 6L device enables patients and healthcare professionals to monitor heart rhythm and promptly detect abnormalities such as atrial fibrillation in real-time. Through Delve Health's platform, Clinical StudyPal, this data can be seamlessly transmitted to healthcare providers, facilitating timely feedback for clinical trials and interventions. This partnership seeks to revolutionize cardiac care by offering a personalized and proactive approach, ultimately leading to improved patient outcomes worldwide.

Furthermore, the collaboration aims to address critical challenges in digital healthcare by passively collecting real-world data (RWD) and real-world evidence (RWE). By integrating AliveCor's device with Delve Health's technology solution, clinical trials can be conducted more efficiently, reducing burdens on sites and patients and enabling sponsors to make informed decisions based on real-time data.

Delve Health's platform, known for its comprehensive, device-agnostic data analytics, empowers healthcare professionals and clinical researchers to derive actionable insights from remotely collected patient data. This solution enables data-driven decision-making, remote patient management, and ultimately leads to more efficient and targeted patient care.

The KardiaMobile 6L device, cleared by the FDA as the first and only six-lead personal EKG, detects a wide range of arrhythmias and provides instant detection of various cardiac conditions. Cardiologists can utilize its readings to measure the QT interval, a significant risk factor for medications and congenital issues.

This collaboration represents a significant milestone in healthcare solutions and underscores both companies' commitment to transforming patient care through cutting-edge technologies.

Source: prnewswire.com